• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Clinical trials with haemopoietic growth factors.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Steward, William P
    Scarffe, J Howard
    Affiliation
    Department of Medical Oncology, Christie Hospital, Withington, Manchester, U.K.
    Issue Date
    1989
    
    Metadata
    Show full item record
    Abstract
    Five glycoprotein growth factors capable of stimulating the proliferation and differentiation of haemopoietic progenitor cells in vitro have been identified and sequenced over the past ten years. Recombinant DNA technology has recently enabled the production of sufficient amounts of these agents for preclinical testing. Erythropoietin (EPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), and granulocyte colony-stimulating factor (G-CSF) have already entered clinical studies in humans. Interleukin-3 (IL-3) and macrophage colony-stimulating factor (M-CSF) should soon be available for use in humans. EPO corrects the anaemia of end stage renal failure, improving the quality of life for such patients and preventing the need for red cell transfusions. At high dose it increases platelet production in vitro and in vivo and may be of value in humans to prevent the thrombocytopaenia associated with chemotherapy. G-CSF and GM-CSF have been used in several clinical studies. Administration of both growth factors results in a leucocytosis, G-CSF predominantly increasing neutrophil production and GM-CSF increasing production of neutrophils, eosinophils and monocytes. The optimal administration of these agents is via continuous intravenous infusion or daily subcutaneous injections at doses of 3-10 micrograms/kg/24 h. GM-CSF has shown promising results in patients with AIDS and the myelodysplastic syndrome and both G-CSF and GM-CSF have reduced the duration of neutropaenia and incidence of infection associated with chemotherapy. These agents may allow an escalation of the dose-intensity of chemotherapy in the future and thereby, hopefully, increase the response rate and survival for patients with a variety of neoplasms. Several other potential roles for these haemopoietic growth factors are discussed.
    Citation
    Clinical trials with haemopoietic growth factors. 1989, 1 (1):1-12 Prog. Growth Factor Res.
    Journal
    Progress in Growth Factor Research
    URI
    http://hdl.handle.net/10541/110853
    DOI
    10.1016/0955-2235(89)90037-9
    PubMed ID
    2491251
    Type
    Article
    Language
    en
    ISSN
    0955-2235
    ae974a485f413a2113503eed53cd6c53
    10.1016/0955-2235(89)90037-9
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Myelodysplastic syndromes: a guide to treatment with epoetin and colony-stimulating factors.
    • Authors: Geissler RG, Ganser A
    • Issue date: 1998 Aug
    • Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
    • Authors: Laughlin MJ, Kirkpatrick G, Sabiston N, Peters W, Kurtzberg J
    • Issue date: 1993 Dec
    • The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes.
    • Authors: Greenberg PL, Negrin R, Nagler A
    • Issue date: 1990
    • Clinical toxicity of cytokines used as haemopoietic growth factors.
    • Authors: Vial T, Descotes J
    • Issue date: 1995 Dec
    • Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    • Authors: Musto P, Sanpaolo G, D'Arena G, Scalzulli PR, Matera R, Falcone A, Bodenizza C, Perla G, Carotenuto M
    • Issue date: 2001 Jan
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.